dyslipidemia
Oct 10, 2022
PCSK9 Inhibitors: A New Era for Cholesterol Management
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
